日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study

奥莫替尼联合卡铂-培美曲塞对比奥莫替尼单药治疗EGFR和伴随肿瘤抑制基因的非小细胞肺癌(ACROSS2):一项开放标签、多中心、随机3期研究

Duan, Jian-Chun; Zhong, Jia; Sun, Bo-Yang; Zhao, Wen-Hua; Wu, Lin; Fei, Kai-Lun; Chu, Qian; Guo, Qi-Sen; Song, Qi-Bin; Yu, Yan; Zhu, Da-Xing; Liu, Xin-Yan; Zhao, Jun; Zhan, Zhi-Xiang; Li, Shi; Nie, Lei; Lin, Jie; Peng, Xiao-Dong; Zhong, Dian-Sheng; Zhou, Jin; Li, Li-Hua; Chen, Yun-Fang; Hu, Chen; Mok, Tony; Wang, Zhi-Jie; Wang, Jie

Spi-1 proto-oncogene regulates mRNA hypertranscription and malignant progression in head and neck cancer

Spi-1原癌基因调控头颈癌中的mRNA过度转录和恶性进展

Liu, Zheran; Qin, Zijian; Li, Huilin; Zhu, Lili; He, Ling; Chen, Na; Zhu, Dan; Liu, Qinghong; Dai, Lei; Peng, Xingchen

Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study

乐伐替尼联合经动脉化疗栓塞术和PD-1抑制剂作为不可切除的中晚期肝细胞癌转化疗法:一项II期临床试验和探索性生物分子研究

Zhang, Xiaoyun; Cai, Haozheng; Peng, Wei; Wang, Haiqing; Wu, JiaYi; Zhu, Xinrui; Guo, Weixin; Xie, Fei; Zhang, Yu; Wang, Ming; Yu, Yu; Zhou, Yongjie; Li, Chuan; Shen, Junyi; Liu, Chang; Yang, Yu; Jiang, Xiaozhong; Li, Qiu; Chen, Weixia; Shi, Yujun; Lu, Wusheng; Sun, Xin; Feng, Xielin; Yan, Maolin; Cheng, Shuqun; Wen, Tianfu

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

一线治疗EGFR突变型非小细胞肺癌患者,比较奥莫替尼(EGFR酪氨酸激酶抑制剂)联合阿帕替尼(VEGFR抑制剂)与奥莫替尼单药治疗的疗效:一项随机、多中心、II期临床试验

Zhang, Fan; Zheng, Zhendong; Zhang, Hongmei; Yan, Xiaolong; Liu, Zhefeng; Yang, Fan; Wen, Juyi; Gan, Xin; Wu, Lin; Cang, Shundong; Wang, Hongmei; Zhao, Jun; Peng, Liang; Li, Xiaosong; Fan, Zaiwen; Shen, Ge; Zhou, Qiong; Zou, Jinjing; Xu, Yu; Zhang, Lei; Zhao, Mingfang; Cai, Shangli; Hu, Yi

The consensus molecular subtypes of esophageal squamous cell carcinoma

食管鳞状细胞癌的共识分子亚型

Cui, Heyang; Zhu, Zhongxu; Xu, Enwei; Qi, Lin; Cheng, Yikun; Zhang, Yinghan; Zhang, Ling; Cheng, Matthew Yibo; Yang, Bin; Sun, Ruifang; Zhuang, Xiaofei; Xi, Yanfeng; Yan, Ting; Cheng, Caixia; Ding, Ning; Liu, Huijuan; Wang, Lu; Guo, Min; Guo, Dinghe; Zhang, Haoyu; Peng, Meilan; An, Zhekun; Weng, Yongjia; Wang, Fang; Liu, Meng; Xiong, Ruixin; Yin, Weihua; Song, Bin; Zhang, Weimin; Cheng, Xiaolong; Liu, Zhihua; Zhan, Qimin; Wang, Xin; Cui, Yongping

Serpina3c protects against metabolic dysfunction-associated steatotic liver disease in offspring induced by prenatal prednisone exposure

Serpina3c 可保护后代免受产前泼尼松暴露引起的代谢功能障碍相关的脂肪肝疾病的影响

Dai, Yongguo; Lu, Zhengjie; Peng, Yu; Liu, Kexin; Lu, Xiaoqian; Sun, Xiaoxiang; Wang, Yuxi; Yan, Xuerong; Chen, Zijie; Zhang, Ziyi; Zhang, Ning; Ailikaiti, Aihemaitijiang; Chen, Yiming; Yue, Quanrui; Guo, Yu; Chen, Liaobin; Wang, Hui

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study

抗PD-1抗体penpulimab联合化疗治疗复发性或转移性鼻咽癌:一项随机、双盲3期研究

Huang, Shuang; Liu, Feng; Qu, Song; Chen, Lisha; Zhou, Ping; Qu, Shenhong; Ai, Xiaohong; Chen, Yong; Liu, Meilian; Wang, Rensheng; Chan, Kelvin Kw; Zhang, Peng; Hu, Chunhong; Wen, Jiyu; Zhang, Jian; Lin, Qin; Li, Xiaojiang; Gu, Kangsheng; Xiang, Li; Wang, Dongxia; Li, Jingao; Lin, Daren; Hu, Desheng; Ding, Jianwu; Wang, Siyang; Huang, Xiaoming; Wang, Lin; Jin, Feng; Pfister, David G; Mak, Milena Perez; Marchi, Pedro Rafael Martins de; Jiang, Yi; Yang, Haihua; Hu, Xiaoye; Liu, Tianrun; Wu, Dehua; Shreenivas, Aditya; Oliveira, Thiago Bueno de; Silva, Carlos Eduardo Baston; Alves, Gustavo Vasconcelos; Li, Xianming; Yao, Zhifang; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Chen, Xiaozhong; Hu, Chaosu; Xu, Tingting

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial

在转移性去势抵抗性前列腺癌患者接受多西他赛和阿比特龙治疗后出现疾病进展的情况下,新型雄激素受体抑制剂氘代沙鲁胺的疗效:来自随机 III 期 HC-1119-04 试验的结果

Wu, Junlong; Li, Xinghai; Gu, Chengyuan; Hua, Lixin; Liu, Ranlu; Li, Jun; Qiu, Mingxing; Guo, Jianming; Dong, Haiying; Ji, Zhigang; Xie, Liping; Zhu, Shaoxing; Zhang, Xuhui; Chen, Peng; Jiang, Shusuan; Sun, Zhongquan; Xu, Danfeng; Chen, Hui; Shi, Benkang; Wang, Yujie; Pu, Jinxian; Perabo, Frank; Chen, Yuanwei; Ye, Dingwei

Endoplasmic reticulum stress in disease pathogenesis: its implications for therapy

内质网应激在疾病发病机制中的作用:其对治疗的意义

Wei, Siyu; Zhang, Nan; Zhang, Hao; Chen, Zigui; Li, Shuyu; Wu, Wantao; Liu, Zaoqu; Xia, Zhiwei; Luo, Peng; Cheng, Quan

Antiviral drug discovery and development: challenges and future directions

抗病毒药物的发现与开发:挑战与未来方向

Du, Shaoqing; Hu, Xueping; Li, Ping; Xu, Shujing; Kim, Meehyein; Liu, Xinyong; Zhan, Peng